Gilead Sciences, Inc. Share Price

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 26/04/2024 BST 5-day change 1st Jan Change
65.42 USD +0.23% Intraday chart for Gilead Sciences, Inc. -2.01% -19.24%
Sales 2024 * 27.54B 2,205B Sales 2025 * 28B 2,241B Capitalization 81.58B 6,530B
Net income 2024 * 391M 31.3B Net income 2025 * 6.43B 515B EV / Sales 2024 * 3.58 x
Net Debt 2024 * 16.88B 1,352B Net Debt 2025 * 9.29B 743B EV / Sales 2025 * 3.25 x
P/E ratio 2024 *
94.4 x
P/E ratio 2025 *
12.4 x
Employees 18,000
Yield 2024 *
4.75%
Yield 2025 *
4.96%
Free-Float 99.9%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.23%
1 week-2.01%
Current month-10.69%
1 month-9.65%
3 months-17.73%
6 months-16.66%
Current year-19.24%
More quotes
1 week
64.63
Extreme 64.63
67.90
1 month
64.63
Extreme 64.63
73.87
Current year
64.63
Extreme 64.63
87.87
1 year
64.63
Extreme 64.63
87.87
3 years
57.17
Extreme 57.165
89.74
5 years
56.56
Extreme 56.56
89.74
10 years
56.56
Extreme 56.56
123.37
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 28/02/19
Director of Finance/CFO 54 31/12/15
Chief Tech/Sci/R&D Officer - 11/04/21
Members of the board TitleAgeSince
Director/Board Member 69 16/10/20
Director/Board Member 71 31/12/17
Director/Board Member 65 01-31
More insiders
Date Price Change Volume
26/04/24 65.42 +0.23% 12,382,425
25/04/24 65.27 -2.70% 15,171,959
24/04/24 67.08 +0.07% 8,467,060
23/04/24 67.03 +0.12% 5,240,249
22/04/24 66.95 +0.28% 5,622,367

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
65.42 USD
Average target price
84.25 USD
Spread / Average Target
+28.78%
Consensus